SC Filed 2023-09-27 Event — SEC 0001193125-23-243214 →

Frazier Life Sciences Public Fund, L.P. → HilleVax, Inc.

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 6/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Passive Schedule 13G filer baseline

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

8 filings by this filer

7 other filings in the data moat

Short Interest

—

Not in latest FINRA snapshot

Other 13D/G Filings on HilleVax, Inc.

Filed	Form	Filer	Stake	Shares
2025-09-17	SCHEDULE	Frazier Life Sciences Public Fund, L.P.	—	—	view →

Other Filings by Frazier Life Sciences Public Fund, L.P.

Filed	Form	Issuer	Stake	Shares
2026-10-09	SCHEDULE 13G	Q32 Bio Inc.	—	—	view →
2026-09-21	SCHEDULE 13G	ACLARIS THERAPEUTICS, INC.	—	—	view →
2026-08-11	SCHEDULE 13D	Attovia Therapeutics, Inc.	13.50%	760,327	view →
2026-08-10	SCHEDULE 13D/A	MBX BIOSCIENCES, INC.	—	1,429,573	view →
2026-05-21	SCHEDULE 13D/A	KalVista Pharmaceuticals, Inc.	2.30%	1,249,165	view →
2025-09-30	SCHEDULE	MBX Biosciences, Inc. MBX	11.70%	5,224,095	view →
2025-09-17	SCHEDULE	HilleVax, Inc.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →